Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

COMBINED THERAPY: Photodynamic Therapy and Bevacizumab to Treat Myopic Neovascular Membranes. One-Year Follow-Up

Desco, M Carmen MD, PhD; Mataix, Jorge MD, PhD; Garcia-Pous, Maria MD, PhD; Palacios-Pozo, Elena MD; Navea, Amparo MD, PhD

doi: 10.1097/IAE.0b013e3181f201a6
Original Study

Purpose: The purpose of this study was to evaluate whether combined customized photodynamic therapy (PDT) and bevacizumab in myopic choroidal neovascularization can improve vision and whether it is possible to decrease the frequency and number of intravitreal antiangiogenic injections.

Methods: A prospective, consecutive, noncomparative, interventional case series of 36 patients with myopic choroidal neovascularization, treated with an initial dose of PDT and intravitreal bevacizumab 48 hours to 60 hours afterward. Retreatments were carried out as required with monthly bevacizumab and PDT every 3 months if there were relapses. Follow-up lasted 1 year in all cases.

Results: The mean best-corrected visual acuity increased from 44 letters before the initial treatment to 59.5 letters at the 12-month follow-up (P < 0.01). Compared with initial vision, 94.5% of the eyes had the same or better vision and 5.5% lost fewer than 6 lines of vision. The mean number of PDT treatments was 1.1 per patient, and the mean number of bevacizumab injections was 1.5 per patient. Only 1 initial treatment with PDT + bevacizumab was necessary in 28 cases (77.8%).

Conclusion: Combined personalized PDT + bevacizumab therapy makes it possible to obtain visual results similar to those obtained in monotherapy studies but with fewer intravitreal injections. It appears to be an interesting option for this type of patient.

We analyzed the response of 36 patients with myopic choroidal neovascularization, treated with PDT + intravitreal bevacizumab, as required, for 12 months. We obtained a similar visual response as that achieved with antivascular endothelial growth factor in monotherapy in other studies but with fewer and less frequent retreatments.

From the Fundación Oftalmológica del Mediterráneo, Valencia, Spain.

Presented at the Joint Congress of SOE/AAO 2007, Vienna, Austria, June 12, 2007.

None of the authors has a commercial or proprietary interest in this study.

Reprint requests: M. Carmen Desco, MD, PhD, Fundación Oftalmológica del Mediterráneo (FOM), Bifurcación Pío Baroja-General Avilés s/n. E46015 Valencia, Spain; e-mail:

© The Ophthalmic Communications Society, Inc.